comprehensive -WSS

comprehensive

author：entertainment 2025-08-26 23:46:52 - browse：19956

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Sutter Health’s antitrust win overturned by appeals court

entertainment

WSS

With clinical trial data readouts, here's how to spot spin

Congress needs to close a vaccine

How CO2 helps viruses stay alive longer in the air

Congress needs to close a vaccine

What don’t we know about an Alzheimer’s drug side effect?

Senators tussle over abortion against the backdrop of a presidential campaign

knowledge

comprehensive

leisure time

Continuity nursing helped my family in our darkest PICU moments

Flagship Pioneering launches a new biotech in two countries

Supreme Court strikes down use of affirmative action

Fight over Supreme Court dialysis ruling puts kidney patients at risk

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

After affirmative action ruling, medical educators look to 'holistic review'

Fight over Supreme Court dialysis ruling puts kidney patients at risk

DIEP, the 'gold standard' of breast reconstruction, is under threat

Take antibiotics after sex, CDC recommends for certain risk groups

explore

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

U.K. Biobank has 500,000 peoples' genome sequences available

Senators tussle over abortion against the backdrop of a presidential campaign

Finland to offer bird flu vaccine to select groups of people, a possible global first

ASCO Daily Recap: CAR

explore

entertainment

entertainment

focus